Factors affecting response and resistance to venetoclax in acute myeloid leukemia
{{output}}
The use of the BCL2 inhibitor venetoclax in combination with hypomethylating agents (HMA) is a revolution for the treatment of frail and elderly acute myeloid leukemia (AML) patients. This effective treatment strategy is increasingly more and more applicable f... ...
